Abstract 4364102: Acoramidis Reduces All-Cause Mortality and Cardiovascular-Related Hospitalizations Through Month 42 in Transthyretin Amyloid Cardiomyopathy Across All Pre-specified Patient Subgroups

Introduction: Acoramidis, an oral transthyretin (TTR) stabilizer achieving near-complete (≥90%) TTR stabilization, is now approved in the USA, EU, Japan, and UK for the treatment of TTR amyloid cardiomyopathy (ATTR-CM). In the 30-month phase 3 ATTRibute-CM study, acoramidis reduced all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) vs placebo. Through Month 42 (M42) of the open-label extension (OLE; 30 months ATTRibute-CM + 12 months OLE), the clinical benefit of acoramidis was sustained, resulting in a 36% and 43% risk reduction in ACM and ACM/first CVH, respectively, compared with the placebo to acoramidis group Research Question: Are the long-term clinical benefits of acoramidis on ACM and ACM/first CVH in ATTR-CM over 42 months consistent across patient subgroups? Methods: ATTRibute-CM study design has been previously described. At the end of the 30-month double-blind period, patients enrolled into OLE continued acoramidis or switched from placebo to acoramidis; all patients received open-label acoramidis HCI 800 mg BID. Data cut was performed after 12 months in OLE. Subgroup analysis for ACM and ACM/first CVH through M42 were conducted for randomization stratification factors (genotype, NT-proBNP, and eGFR levels) and other pre-specified subgroups. ACM included death due to any cause, cardiac mechanical assist device placement, and heart transplant. CVH included CV hospitalizations (≥24 h) and urgent visits (<24 h) for decompensated heart failure requiring IV diuretics and was adjudicated by an independent Clinical Events Committee. Results: Overall, 389 patients enrolled in the OLE (263 continuous acoramidis and 126 placebo to acoramidis). The analyses of ACM/first CVH ( Figure 1 ) and ACM ( Figure 2 ) through M42 consistently favored patients initially randomized to acoramidis across all patient subgroups, including those based on sex, age, country, ATTR-CM genotype, baseline NT-proBNP, baseline eGFR, NYHA class, and NAC stage. The largest effect size for the reduction in ACM/first CVH (HR <0.50) was observed in the following subgroups: female, non-Caucasian patients, variant ATTR-CM, or NAC stage 2. Conclusions: The long-term benefit of acoramidis was consistently shown in patients initially randomized to acoramidis treatment compared with placebo to acoramidis switch after 30 months across multiple clinically relevant subgroups, underscoring the importance of early initiation of acoramidis to reduce the long-term risk of ACM or CVH.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.